BioN­Tech signs im­munother­a­py deal with Medi­gene as post-Covid strat­e­gy takes shape

Con­tin­u­ing to chart its path for­ward post-pan­dem­ic, BioN­Tech struck a new deal Mon­day aimed at boost­ing its pres­ence in on­col­o­gy.

The Covid-19 vac­cine mak­er signed a col­lab­o­ra­tion with Ger­many’s Medi­gene, the com­pa­nies an­nounced, giv­ing BioN­Tech the rights to a pre­clin­i­cal T cell re­cep­tor (TCR) pro­gram and li­cens­es to oth­er Medi­gene tech­nolo­gies. In re­turn, Medi­gene re­ceived about $29.5 mil­lion in up­front cash and will be el­i­gi­ble for mile­stones de­scribed on­ly as “pay­ments up to a triple dig­it mil­lion EUR amount per pro­gram.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER